## **Trustees’ Annual Report for the period** ## **From Period start date 26/09/2021 To Period end date 25/09/2022** **Charity name: SICKLEKAN SICKLE CELL FOUNDATION** ## **Charity registration number: 1174838** ## **Objectives and Activities** ||SORP reference|| |---|---|---| |Summary of the purposes of
the charity as set out in its
governing document|Para 1.17|**TO RELIEVE THE NEEDS OF PEOPLE**
**AFFECTED BY SICKLE CELL DISEASE,**
**THEIR FAMILIES AND CARERS FOR**
**THE PUBLIC BENEFIT BY: 1)**
**IMPROVING AWARENESS OF SICKLE**
**CELL DISEASE FOR THE GENERAL**
**PUBLIC, SERVICE AND HEALTH CARE**
**PROVIDERS; 2) ENABLING PEOPLE**
**AFFECTED BY SICKLE CELL DISEASE**
**TO RAISE AWARENESS OF THEIR**
**NEEDS IN THEIR LOCAL AND WIDER**
**COMMUNITIES; 3) SUPPORTING THE**
**PROVISION OF SUITABLE**
**ADJUSTMENTS TO CATER FOR THE**
**NEEDS OF PEOPLE WITH SICKLE CELL**
**DISEASE.**| |Summary of the main
activities in relation to those
purposes for the public
benefit, in particular, the
activities, projects or
services identified in the
accounts.|Para 1.17 and
1.19|**1)TO HELP SUPPORT AND PROVIDE**
**GUIDANCE FOR CHILDREN PARENTS**
**AND FAMILIES AFFECTED BY SICKLE**
**CELL DISEASE**
**2)TO ENCOURAGE MORE BLOOD**
**DONORS FOR SICKLE CELL PATIENTS**
**NEEDING BLOOD TRANSFUSIONS**
**3)TO PROVIDE HELP AND GUIDANCE**
**TO SCHOOLS, BUSINESSES AND**
**AUTHORITIES THAT HAVE MEMBERS**
**THAT HAVE SICKLE CELL DISEASE**
**4) TO PROVIDE A PLATFORM FOR**
**SICKLE CELL PATIENTS TO HAVE A**
**VOICE**
**5) TO PROVIDE A BETTER FUTURE FOR**
**THE NEXT GENERATION OF SICKLE**
**CELL PATIENTS**| ||Para 1.18|| **Additional information (optional)** ## You may choose to include further statements where relevant about: SORP reference Para 1.38 Policy on grant making Para 1.38 Policy on social investment including program related investment Para 1.38 Contribution made by volunteers Other ## **Achievements and Performance** ||SORP reference|| |---|---|---| |Summary of the main
achievements of the charity,
identifying the difference the
charity’s work has made to
the circumstances of its
beneficiaries and any wider
benefits to society as a
whole.|Para 1.20|**Sicklekan Sickle Cell foundation has**
**slowly recovered from the early end of**
**2020 as The Covid 19 pandemic affected**
**the country and our ability to do**
**outreach and support with the founder**
**of the charity affected heavily from**
**Covid 19. However during the following**
**year Of 2020-2021 we have resumed**
**some of our main objectives. During the**
**2021-2022 year due to the founders**
**health issues and scares we have had to**
**scale back efforts slightly to the**
**following.**
**Our activities have been split between**
**a few virtual events via zoom, telephone**
**and teams calls as well as online**
**campaigning. As well as a few face to**
**face counselling and outreach services**
**Even though this year was an**
**improvement on the previous year**
**which was very challenging for us the**
**charity has still upheld its ethos of**
**promoting awareness of sickle cell and**
**assisting the local and wider community**
**of sickle cell patients the best way we**
**can.**| **No Physical Fundraising but the Owner was able to raise some money for the charity privately to help operations.** **We continue to hear and help the patients in need while advocating for awareness, while also supporting patients who reach out to our organisation suffering from mistreatment at hospitals** ## **Additional information (optional)** You may choose to include further statements where relevant about: |
Achievements against
objectives set|
Para 1.41|| |---|---|---| |Performance of fundraising
activities against objectives
set|Para 1.41|| |Investment performance
against objectives|Para 1.41|| |Other||| ## **Financial Review** Review of the charity’s Para 1.21 financial position at the end of the period Statement explaining the Para 1.22 policy for holding reserves stating why they are held Amount of reserves held Para 1.22 Reasons for holding zero Para 1.22 reserves Details of fund materially in Para 1.24 deficit Explanation of any Para 1.23 uncertainties about the charity continuing as a going concern ## **Additional information (optional)** ## You may choose to include further statements where relevant about: |
The charity’s principal
sources of funds (including
any fundraising)|
Para 1.47|| |---|---|---| |Investment policy and
objectives including any
social investment policy
adopted|Para 1.46|| |A description of the principal
risks facing the charity|Para 1.46|| |Other||| ## **Structure, Governance and Management** |Description of charity’s
trusts:||| |---|---|---| |Type of governing document
(trust deed, royal charter)|Para 1.25|**Charter**| |How is the charity
constituted?
(e.g unincorporated
association, CIO)|Para 1.25|**CIO**| |Trustee selection methods
including details of any
constitutional provisions e.g.
election to post or name of
any person or body entitled
to appoint one or more
trustees|Para 1.25|**Interview process then vote then**
**selection**| ## **Additional information (optional)** ## You may choose to include further statements where relevant about: |
Policies and procedures
adopted for the induction
and training of trustees|
Para 1.51|| |---|---|---| |The charity’s organisational
structure and any wider
network with which the
charity works|Para 1.51|| |Relationship with any related
parties|Para 1.51|| |Other||| ## **Reference and Administrative details** |Charity name|Sicklekan Sickle Cell Foundation| |---|---| |Other name the charity uses|| |Registered charity number|1174838| |Charity’s principal address|Flat 3 Hay House Border crescent London SE26 6DD| ||| **Names of the charity trustees who manage the charity** |1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20|**Trustee name**|**Office (if any)**|**Dates acted if not for whole**
**year**|**Name of person (or body) entitled**
**to appoint trustee (ifany)**| |---|---|---|---|---| ||Kehinde Salami|||| ||Lanre Owolabi|||| ||Iman Davidson
Fuller|||| |||||| |||||| |||||| |||||| |||||| |||||| |||||| |||||| |||||| |||||| |||||| |||||| |||||| |||||| |||||| |||||| |||||| ## – Corporate trustees names of the directors at the date the report was approved **Director name** Name of trustees holding title to property belonging to the charity **Trustee name Dates acted if not for whole year** ## **Funds held as custodian trustees on behalf of others** Description of the assets held in this capacity Name and objects of the charity on whose behalf the assets are held and how this falls within the custodian charity’s objects Details of arrangements for safe custody and segregation of such assets from the charity’s own assets ## **Additional information (optional)** ## **Names and addresses of advisers (Optional information)** **Type of Name Address adviser** **Name of chief executive or names of senior staff members (Optional information)** ## **Exemptions from disclosure** Reason for non-disclosure of key personnel details ## **Other optional information** ## **Declarations** **The trustees declare that they have approved the trustees’ report above.** **Signed on behalf of the charity’s trustees** **Signature(s)** Kehinde Salami **Full name(s)** Kehinde Salami **Position (eg Secretary,** Founder, Director **Chair, etc)** **Date** 27/07/2021 **Sicklekan Sickle Cell Foundation No (if any) 1174838 Receipts and payments accounts For the period** Period start date 9/25/2022 **To from** 9/26/2021 ## **CC16a** ## **Section A Receipts and payments** |**Section A Receipts and payments**||||| |---|---|---|---|---| |**Income**
**A1 Receipts**
**10,000**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**10,000**
**-**
**-**
**_Sub total_ -**
**_Total receipts_ 10,000**
**A3 Payments**
WEBSITE
**880**
POSTAGE AND PACKAGING
**870**
GAS AND ELECTRIC
**650**
TRAVEL
**290**
TEESHIRTS AND FLYERS
**780**
ADVERTISING
**230**
OTHER
**600**
**-**
**-**
**_Sub total_ 4,300**
**-**
**-**
**_Sub total_ -**
**_Total payments_ 4,300**
**_Net of receipts/(payments)_ 5,700**
**A5 Transfers between funds**
**-**
**A6 Cash funds last year end**
**-**
**_Cash funds this year end_ 5,700**
**Unrestricted**
**funds**
**to the nearest £**
**_Sub total_**_(Gross income for AR)_
**A2 Asset and investment sales,**
**(see table).**
**A4 Asset and investment**
**purchases, (see table)**|**to the nearest £**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**Restricted**
**funds**|**to the nearest £**
**Endowment**
**funds**|**Total funds**
**to the nearest £**
**10,000**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**10,000**
**-**
**-**
**-**
**10,000**
**880**
**870**
**650**
**290**
**780**
**230**
**600**
**-**
**-**
**4,300**
**-**
**-**
**-**
**4,300**
**5,700**
**-**
**-**
**5,700**|**Last year**
**to the nearest £**| |||**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**|**10,000**|**4,000**| ||||**-**|**-**| ||||**-**|**-**| ||||**-**|**-**| ||||**-**|**-**| ||||**-**|**-**| ||||**-**|**-**| ||||**-**|**-**| ||||**10,000**|**4,000**| |||||| |||**-**
**-**
**-**|**-**|| ||||**-**|**-**| ||||**-**|**-**| |||||| |||**-**|**10,000**|**4,000**| |||||| |||**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**|**880**|**1,100**| ||||**870**|**400**| ||||**650**|**400**| ||||**290**|**250**| ||||**780**|**650**| ||||**230**|**300**| ||||**600**|**200**| ||||**-**|**-**| ||||**-**|**-**| ||||**4,300**|**3,300**| |||||| |||**-**
**-**
**-**|**-**|| ||||**-**|| ||||**-**|**-**| |||||| |||**-**|**4,300**|**3,300**| |||||| ||**-**|**-**
**-**
**-**
**-**|**5,700**|**700**| ||**-**||**-**|**-**| ||**-**||**-**|**-**| ||**-**||**5,700**|**700**| ## **Section B Statement of assets and liabilities at the end of the period** |**Categories**
**B1 Cash funds**
**B2 Other monetary assets**
**B3 Investment assets**
**B5 Liabilities**
**B4 Assets retained for the**
**charity’s own use**
Signed by one or two trustees on
behalf of all the trustees|**Details**
**Details**
**Details**
**Details**
**Details**
Signature
Kehinde Salami
**_Total cash funds_**
(agree balances with receipts and payments
account(s))|**to nearest £**
**to nearest £**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
Agreement Error
OK
**to nearest £**
**to nearest £**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**Cost (optional)**
**-**
**-**
**-**
**-**
**-**
**Cost (optional)**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
Print Name
Kehinde Salami
**Unrestricted**
**funds**
**Restricted**
**funds**
**Unrestricted**
**funds**
**Restricted**
**funds**
**Fund to which**
**asset belongs**
**Fund to which**
**asset belongs**
**Fund to which**
**liability relates**
**Amount due**
**(optional)**|**to nearest £**
**Endowment**
**funds**| |---|---|---|---| ||||**-**| ||||**-**| ||||**-**| ||||**-**| ||||OK| ||||**to nearest £**
**Endowment**
**funds**| ||||**-**| ||||**-**| ||||**-**| ||||**-**| ||||**-**| ||||**-**| ||||**Current value**
**(optional)**| ||||**-**| ||||**-**| ||||**-**| ||||**-**| ||||**-**| ||||**Current value**
**(optional)**| ||||**-**| ||||**-**| ||||**-**| ||||**-**| ||||**-**| ||||**-**| ||||**-**| ||||**-**| ||||**-**| ||||**When due**
**(optional)**| ||||| ||||| ||||| ||||| ||||| ||||| ||||Date of
approval| ||Kehinde Salami|Kehinde Salami|2707/2022| |||||